U.S.-led-american companies said Thursday they expect to be able to produce enough antiviral drugs, remdesivir, in October to meet global demand during the new coronavirus pandemic. In addition, the company said it plans to produce more than 2m more courses of Redsiwe by the end of the year and expects to be able to produce “millions” more next year, adding that it has increased the supply of the drug more than 50 times since January.
No drug has yet been approved by the U.S. Food and Drug Administration (FDA) to treat new coronary pneumonia, but doctors have been using the intravenous drug in patients with new coronary pneumonia in recent months.
Studies have shown that it helps shorten the recovery time of some hospitalized patients. In May, the FDA approved Redseyway’s emergency use authorization, allowing hospitals and doctors to use the drug for patients with new coronary pneumonia in patients, although the drug has not yet been formally approved by the agency.